These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 3776576)

  • 1. Trace metals and degenerative diseases of the skeleton.
    Savory J; Bertholf RL; Wills MR
    Acta Pharmacol Toxicol (Copenh); 1986; 59 Suppl 7():282-8. PubMed ID: 3776576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and management of bone disorders in chronic renal failure and dialyzed patients.
    Tzamaloukas AH
    Med Clin North Am; 1990 Jul; 74(4):961-74. PubMed ID: 2195265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients.
    D'Haese PC; Couttenye MM; Lamberts LV; Elseviers MM; Goodman WG; Schrooten I; Cabrera WE; De Broe ME
    Clin Chem; 1999 Sep; 45(9):1548-56. PubMed ID: 10471660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aluminium toxicity in chronic renal insufficiency.
    Savory J; Bertholf RL; Wills MR
    Clin Endocrinol Metab; 1985 Aug; 14(3):681-702. PubMed ID: 3905084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of the deferoxamine infusion test in the diagnosis of aluminum-related osteodystrophy.
    Milliner DS; Nebeker HG; Ott SM; Andress DL; Sherrard DJ; Alfrey AC; Slatopolsky EA; Coburn JW
    Ann Intern Med; 1984 Dec; 101(6):775-9. PubMed ID: 6208838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease.
    Felsenfeld AJ; Rodriguez M; Coleman M; Ross D; Llach F
    Kidney Int; 1989 Jun; 35(6):1371-8. PubMed ID: 2770115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis].
    Wang G; Zhu P; Wang S
    Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and treatment of aluminium bone disease.
    D'Haese PC; Couttenye MM; De Broe ME
    Nephrol Dial Transplant; 1996; 11 Suppl 3():74-9. PubMed ID: 8840316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent developments in aluminum toxicology.
    Monteagudo FS; Cassidy MJ; Folb PI
    Med Toxicol Adverse Drug Exp; 1989; 4(1):1-16. PubMed ID: 2651849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis.
    Faugere MC; Arnala IO; Ritz E; Malluche HH
    J Lab Clin Med; 1986 Jun; 107(6):481-7. PubMed ID: 3486929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of desferrioxamine on aluminum kinetics during hemodialysis.
    Stummvoll HK; Graf H; Meisinger V
    Miner Electrolyte Metab; 1984; 10(4):263-6. PubMed ID: 6749073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive prediction of aluminum bone disease in hemo- and peritoneal dialysis patients.
    Pei Y; Hercz G; Greenwood C; Sherrard D; Segre G; Manuel A; Saiphoo C; Fenton S
    Kidney Int; 1992 May; 41(5):1374-82. PubMed ID: 1614052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
    D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
    Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspects of aluminum toxicity.
    Hewitt CD; Savory J; Wills MR
    Clin Lab Med; 1990 Jun; 10(2):403-22. PubMed ID: 2197055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
    Marumo F; Umetani N; Sato N; Takahashi Y
    J UOEH; 1987 Mar; 9 Suppl():140-52. PubMed ID: 3602745
    [No Abstract]   [Full Text] [Related]  

  • 17. [Aluminic intoxication in chronic hemodialysis. A diagnosis rarely evoked nowadays. Clinical case and review of the literature].
    Seidowsky A; Dupuis E; Drueke T; Dard S; Massy ZA; Canaud B
    Nephrol Ther; 2018 Feb; 14(1):35-41. PubMed ID: 29174672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of fracturing renal osteodystrophy by desferrioxamine.
    Ackrill P; Day JP; Garstang FM; Hodge KC; Metcalfe PJ; Benzo Z; Hill K; Ralston AJ; Ball J; Denton J
    Proc Eur Dial Transplant Assoc; 1983; 19():203-7. PubMed ID: 6878234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aluminum and renal osteodystrophy.
    Nebeker HG; Coburn JW
    Annu Rev Med; 1986; 37():79-95. PubMed ID: 3085581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of desferrioximine in dialysis-associated aluminium disease.
    Ackrill P; Day JP
    Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.